Work

Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide (CYC) in children and young adults with refractory solid tumors.

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.15_suppl.9500

Authors: V. M. Santana, S. D. Baker, B. McCarville, C. F. Stewart, J. Wu, C. Billups, S. L. Spunt, W. L. Furman, L. M. McGregor, S. Hu, J. C. Panetta, W. E. Reddick, A. Davidoff, W. H. Leung, F. Navid

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2271086433

Cites:

Cited by: 3

Related to: 10